Addex Therapeutics Ltd (ADXN) is a Biotechnology company in the Healthcare sector, currently trading at $7.20. It has a SharesGrow Score of 66/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is ADXN = $30 (+316.6% upside).
Valuation: ADXN trades at a trailing Price-to-Earnings (P/E) of -0.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.04.
Financials: revenue is $404,102, -37.6%/yr average growth. Net income is $7M, growing at +60.2%/yr. Net profit margin is 1746% (strong). Gross margin is -109.9% (+229.6 pp trend).
Balance sheet: total debt is $41,994 against $10M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 4.42 (strong liquidity). Debt-to-assets is 0.4%. Total assets: $11M.
Analyst outlook: 1 / 1 analysts rate ADXN as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 25/100 (Fail), Health 67/100 (Partial), Moat 15/100 (Fail), Future 100/100 (Pass), Income 100/100 (Pass).
